What are the detection indicators for using vigabatrin/vigabatrin in the treatment of epilepsy?

When using Vigabatrin/vigabatrin to treat epilepsy, in addition to evaluating the drug's effectiveness in controlling seizures, some specific tests are required to ensure patient safety and minimize side effects. Common detection indicators include:

1. Retinal function monitoring: A significant risk of using Vigabatrin is that it may cause retinal toxicity, especially patients who use it for a long time may suffer from visual field defects and even vision loss. Therefore, regular eye examinations are required during treatment, especially for patients who have used it for more than 3 months. Eye examinations should be more frequent. Vision exams are usually recommended every six months, along with visual field testing to monitor changes in the retina.

2. Liver and kidney function test: Vigabatrin has little impact on liver and kidney function, but long-term use of the drug may put pressure on the liver and kidney function of some patients. Therefore, doctors usually monitor the patient's liver and kidney function during treatment, including regular checks of liver enzyme levels in the blood, urine routine, etc., in order to detect potential liver and kidney damage early.

3. Routine blood monitoring: Because some patients may have side effects of the blood system, regular blood routine testing is crucial to ensure the safety of treatment. This test can help detect problems such as anemia, leukopenia, or thrombocytopenia, allowing early intervention.

4. Blood drug concentration monitoring: Although Vigabatrin does not require precise blood drug concentration monitoring like some anti-epileptic drugs, in some special cases, doctors may choose to monitor the drug concentration to ensure that it is within the effective therapeutic range, especially in the case of drug adjustment or individual patient differences.

Through the above-mentioned regular examinations, doctors can better evaluate the therapeutic effect and safety of Vigabatrin, adjust the treatment plan in a timely manner, reduce possible side effects, and ensure that patients can obtain the maximum therapeutic benefits from the drug.

Reference materials:https://www.sabril.net/